Trade Report: Today, Piper Jaffray Cos. Analysts Give Cellectis SA (CLLS) a $41.00 Price Target

Today, Piper Jaffray Cos. Analysts Give Cellectis SA (CLLS) a $41.00 Price Target

Piper Jaffray Cos. set a $41.00 price objective on Cellectis SA (NASDAQ:CLLS) in a research note issued to investors on Thursday morning. The brokerage currently has a buy rating on the stock.

Other analysts have also issued research reports about the company. Jefferies Group reiterated a buy rating and issued a $47.00 price target on shares of Cellectis SA in a report on Friday, September 9th. Zacks Investment Research upgraded Cellectis SA from a hold rating to a buy rating and set a $21.00 price target for the company in a report on Thursday, October 20th. Finally, Oppenheimer Holdings Inc. reiterated an outperform rating and issued a $65.00 price target on shares of Cellectis SA in a report on Wednesday, September 14th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $42.33.

Shares of Cellectis SA (NASDAQ:CLLS) opened at 17.40 on Thursday. The firm has a 50 day moving average price of $18.69 and a 200-day moving average price of $25.02. Cellectis SA has a 12-month low of $16.35 and a 12-month high of $34.99.

Several institutional investors have recently modified their holdings of the company. Baker BROS. Advisors LP acquired a new position in shares of Cellectis SA during the third quarter worth about $1,204,000. Lazard Asset Management LLC increased its position in shares of Cellectis SA by 3.7% in the third quarter. Lazard Asset Management LLC now owns 285,175 shares of the company’s stock worth $6,867,000 after buying an additional 10,120 shares during the last quarter. Susquehanna International Group LLP acquired a new position in shares of Cellectis SA during the third quarter worth about $281,000. HighTower Advisors LLC increased its position in shares of Cellectis SA by 0.9% in the third quarter. HighTower Advisors LLC now owns 13,565 shares of the company’s stock worth $327,000 after buying an additional 125 shares during the last quarter. Finally, Morgan Stanley increased its position in shares of Cellectis SA by 1,034.6% in the third quarter. Morgan Stanley now owns 64,817 shares of the company’s stock worth $1,561,000 after buying an additional 59,104 shares during the last quarter. 19.79% of the stock is currently owned by institutional investors and hedge funds.

Cellectis SA Company Profile

Related posts

Leave a Comment